Involvement of the pharmaceutical and biotechnology industry is fundamental in achieving the mission of the Alliance. This sector can contribute knowledge and resources needed to drive novel drug discovery and development in progressive MS.

Industry participates in the work of the Alliance through the Industry Forum, the venue for industry members to provide advice and recommendations to the Alliance Scientific Steering Committee and contribute financial support towards the ongoing research initiatives of the Alliance.


Marco Salvetti, Director, Neurology Unit, Sant’Andrea University Hospital, Rome; Director, PhD Programme on Clinical and Experimental Neurosciences and Psychiatry, Sapienza University of Rome, (IT)
Robert Hyde, Senior Director Global Medical Affairs, Biogen, (US)


Shibi Belachew, Vice President, Personalizing Vice President, Personalizing Health Research, Analytics and Solutions, Biogen, (CH)
Gerben Bouma, Clinical Biomarker Lead, GlaxoSmithKline, (UK)
Licinio Craveiro, Neurologist, Senior Global Medical Director, Genentech Roche, (CH/PT)
Kate Daniels, Manager, International Progressive MS Alliance, (US)
Fernando Dangond, Head of Global Clinical Development, Neurology, EMD Serono, (US)
Shawna Golden, Associate Vice President, Global Initiatives, International Progressive MS Alliance, (US)
Ralph Kern, President & Chief Medical Officer, Brainstorm Cell Therapeutics, (US)
Kiren Kresa-Reahl, Senior Medical Director, Clinical Sciences (Neurology), Atara Biotherapeutics, Inc., (US)
Andreas Muehler, Chief Medical Officer, Immunic Therapeutics, (DE)
Ashish Pradhan, Executive Director Neuroimmunology, Disease Area Lead – Medical Affairs, Genentech, (US)
Laura Rapley, Scientific Lead, Chronic Inflammatory Diseases, GlaxoSmithKline, (UK)
Nikolaos Sfikas, Senior IIS Global Group Head, Novartis, (FR)
Kathy Smith, Consultant, International Progressive MS Alliance, (US)
Sana Syed, Senior Medical Director, Clinical Lead, Sanofi, (US)
Davorka Tomic, Head Global Clinical Development in MS, Merck (EMD Serono), (US)
Johan van Beek, Head of Personalized Healthcare Solutions, Biogen, (CH)
Florian von Raison, Clinical Development Head Neuroscience, Global Drug Development, Novartis, (FR)
Erik Wallström, Therapeutic Area Head, Neurology, Sanofi, (US)
Paola Zaratin, Director of Scientific Research, AISM — Italian MS Society, (IT)

Join Us.

Together we are stronger than progressive MS.

Join Us.